Beximco Pharmaceuticals Ltd. has got approval from the Directorate General of Drug Administration (DGDA) to import the COVID-19 vaccine developed by the University of Oxford and AstraZeneca.
Ayub Hossain, spokesperson of DGDA, told BSS tonight that the drug regulatory authority has given a No Objection Certificate (NOC) to Beximco Pharma to import the vaccine from Serum Institute of India.
At a press conference today, Health and Family Welfare Minister Zahid Maleque said Bangladesh will get COVID-19 vaccine doses in time as the country signed an agreement with the Serum Institute of India.
The press conference was held in the conference room of the Health and Family Welfare Ministry.
“Under the agreement, Bangladesh government will get three crore COVID-19 vaccine doses from the Serum Institute of India,” the health minister added.
On December 13, the agreement was signed for collecting three crore COVID-19 vaccine doses developed by the University of Oxford and AstraZeneca.
On November 5, a tripartite Memorandum of Understanding (MoU) was signed for collecting these three crore COVID-19 vaccine doses from the University of Oxford and AstraZeneca. The MoU was signed among the Bangladesh Government, Beximco Pharmaceuticals Ltd. (BPL) and the Serum Institute of India (SII).
The health ministry sources said 1.5 crore people will be administered by these three crore vaccine doses. As each person needs to be vaccinated twice they said, adding 50 lakh people in the country will be administered per month.
